Combination therapy with clomiphene citrate and anastrozole is a safe and effective alternative for hypoandrogenic subfertile men
| Autor: | James M. Hotaling, Jeremy B. Myers, Sorena Keihani, Nathan J. Alder, Gregory J. Stoddard |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Infertility medicine.medical_specialty Combination therapy Urology 030232 urology & nephrology Anastrozole Semen Semen analysis Clomiphene Male infertility 03 medical and health sciences 0302 clinical medicine medicine Humans Infertility Male 030219 obstetrics & reproductive medicine medicine.diagnostic_test business.industry Hypogonadism Estrogen Antagonists Testosterone (patch) medicine.disease Treatment Outcome business Body mass index Follow-Up Studies medicine.drug |
| Zdroj: | BJU International. 122:688-694 |
| ISSN: | 1464-4096 |
| DOI: | 10.1111/bju.14390 |
| Popis: | Objectives To assess the efficacy and safety of combination therapy with clomiphene citrate (CC) and anastrozole (AZ) for male hypoandrogenism. Patients and methods We identified patients treated with a combination of CC + AZ in the period 2014 to 2017. Data were gathered on patient characteristics and laboratory values at baseline. Total testosterone, bioavailable testosterone, oestradiol and testosterone:oestradiol ratio were measured before combination therapy (treatment with CC only) and at CC + AZ combination therapy follow-ups. Treatment side effects were recorded; prostatic-specific antigen and haematocrit levels were measured to assess safety after 6 months. As a secondary outcome, semen characteristics were compared at baseline and after at least 3 months of combination therapy when these data were available. Data were analysed using a paired t-test and Wilcoxon's signed-rank test. Results A total of 51 men were included, with a mean age of 35.4 ± 7.4 years and a mean body mass index of 35.0 ± 8.0 kg/m2 . After CC treatment, total testosterone, bioavailable testosterone, and oestradiol levels all significantly increased. AZ was added in all patients with hyperoestrogenaemia (oestradiol >50 pg/mL) or a testosterone:oestradiol ratio 54%) haematocrit, n = 2. Conclusion Combination therapy with CC + AZ is an effective and safe alternative for patients with elevated oestradiol level or low testosterone:oestradiol ratio. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text